Organization | Pierrel Research

Pierrel Research Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Sesto San Giovanni Italy (1988)

Organization Overview

First Clinical Trial

2009

NCT00901654

First Marketed Drug

2010

epinephrine (levophed)

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PIERREL | Pierrel Research Europe GmbH | Pierrel Research HP-RO | Pierrel Research USA, Inc. | Therametrics

Active Ingredients

Marketed Drugs (2)

articaine (Septocaine) (2010)

epinephrine (levophed) (2010)

Drugs in Phase 3 Trials (9)

Key: Pierrel Research (8) Acquired (1)

177lu-dota0-tyr3-octreotate (Dotatate) (1 trial)

C1 Esterase Inhibitor (Human) (Cinryze) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

ferrous sulfate (1 trial)

ganciclovir (cytovene) (1 trial)

octreotide (sandostatin) (1 trial)

polyethylene glycol (2 trials)

prucalopride (1 trial)

valganciclovir (Valcyte) (1 trial)

Drugs in Phase 2 Trials (6)

Key: Pierrel Research (4) Acquired (2)

ace527 (2 trials)

atorvastatin (lipitor) (2 trials)

birch allergen (1 trial)

busulfan (Myleran) (1 trial)

interferon beta-1b (betaseron) (2 trials)

treosulfan (1 trial)

Drugs in Phase 1 Trials (1)

betahistine mesilate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Asthma (Phase 2)

Carcinoid Tumor (Phase 3)

Colorectal Neoplasms (Phase 1)

Conjunctivitis (Phase 2)

Constipation (Phase 3)

Diarrhea (Phase 2)

Hemoglobinopathies (Phase 2)

Metabolism, Inborn Errors (Phase 2)

Neoplasms (Phase 3)

Neuroendocrine Tumors (Phase 3)

Pancytopenia (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial APIs: 16